TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sensitivity of the Yale Swallow Protocol (YSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle isokinetic strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to talimogene laherparepvec alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Best overall response rate to talimogene laherparepvec and nivolumab combination therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: DNA methylation pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cosmetic Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: median door-to-balloon time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum antibiotic concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency Room Visit or Hospitalization for Acute Decompensated Heart Failure (ADHF)
Endpoint domain: Mortality/survival
Primary endpoint: Cough specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total number of resected lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anorectal functional outcome at 12 months assessed by COREFO questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Anorectal functional outcome at 12 months assessed by LARS scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bone Resorption (Exercise)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone Resorption (Calcitriol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone Formation (Exercise)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone Formation (Calcitriol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving BASDAI 50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Exposure to IDELA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of Administration of IDELA
Endpoint domain: Adverse events/effects
Primary endpoint: shoulder internal rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: shoulder external rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: hand behind neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: hand behind back
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cardiorespiratory fitness (CRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline arterial blood gas values for pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline arterial blood gas value for bicarbonate (mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline serum troponin (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median Percent Change in Drop Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Pain rate using Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subject Responders With Antigen Specific Th2 CD4+ T Cells Expressing Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of cilioretinal arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change of NK cell activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative Number of New Gadolinium [Gd]-Enhancing T1-weighted Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants With Measurable Plasma Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Activated and Memory T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Serum Cytokines: CXCL9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Serum Cytokines CXCL10 (IP10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean CD4 T Cell Infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean CD8 T Cell Infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Clients with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Disease control rate at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination of inflammatory and infectious arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC[0-tlast]) of Sorafenib in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Drug Concentration (Cmax) of Sorafenib in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol drink/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of recovery (QoR40)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VAS of brachial plexus innervated area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance on the six minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children answering correctly to mathematical questions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Craniocervical posture change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharyngeal airway change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hyoid bone position change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain metabolic activity (FDG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Loss During Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bacterial profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ICDAS assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCV plasmatic viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the plasma drug concentration versus time curve (AUC(0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma drug concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TESS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MSTS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Severity of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in health status and symptom relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Treatment Failure (PI Comparison)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Treatment Failure (NRTI Comparison)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily ocular itching and redness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short latency intracortical inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in clinician-administered LSAS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LSAS Fear subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LSAS Avoidance subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiovascular death and/or hospitalization for worsening heart failure
Endpoint domain: Mortality/survival
Primary endpoint: 2 Year Failure Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Post Prandial Glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breathe hydrogen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cervicovaginal fluid milieu
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choreatic dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dystonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: self-assessment accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to optimal antibiotic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: brachial artery vascular patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Postoperative IOL tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative IOL decentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's Global Assessment of Redness (IGA-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Identification of pain in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment for acute pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects of acute pain therapeutics
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in the Montgomery-Åsberg Depression Rating Scale Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood flow display ratio of SMI in the median nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Virologic clearance in nasopharyngeal swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfer to ICU
Endpoint domain: Mortality/survival
Primary endpoint: Virologic clearance in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hip Abduction Dynamometer test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: No negative impact on sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Response to high-dose aldesleukin (IL-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage Change in Lipoprotein(a) at Week 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radiographic progression-free survival (rPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Childhood asthma control test (C-ACT) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of times got Admissions due to asthma in the last 4 weeks
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Count of participants alive and free of respiratory failure at Day 29
Endpoint domain: Mortality/survival
Primary endpoint: Peel force used to remove adhesive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Minimum effective volume (95%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe Hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Diabetic Ketoacidosis
Endpoint domain: Adverse events/effects
Primary endpoint: LOOH and MDA-DNA adducts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in VAS score for pain at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of RBC Units Transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of PRBC Transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ovarian reserve modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Local Control Rate
Endpoint domain: Mortality/survival
Primary endpoint: Bronchial Threshold to Allergen Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in patient reported satisfaction with understanding of bulge symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median disease free survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of plasma RNA HIV viral rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Composite rate of death, myocardial infarction, and urgent target vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Safety of SBRT in OP malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of SBRT in OP malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of SBRT in OP malignancies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of participants correctly classified for aMCI diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of participants correctly predicted for conversion from aMCI to AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hydrogen value in the expired air
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in S-100B and NSE concentrations in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinician-Administered PTSD Scale, 5th Edition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Attendance/Dropout
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Escalation in dosing amount or frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of occurrence of P. falciparum parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in scores on the Liebowitz Social Anxiety Scale-self report version (LSAS-SR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in behavioral avoidance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in scores on the Clinical Global Improvement Scale, Patient Report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Shock-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: sTREM1 grade 2 adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: sTREM2 grade 2 adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in modified Total Sharp Score (mTSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Evidence of Prior SARS-CoV-2 Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Current SARS-CoV-2 Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Incidence of SARS-CoV-2 Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Trunk involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone Union
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief in nonunion area
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: satisfaction with impression technique
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: satisfaction with final implant restoration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vago-sympathetic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report measures of alcohol-related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective measures of alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident dementia diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Moderate decline in cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of adults eligible for the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of eligible patients recruited into the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of study participants who successfully completed the physical and the psychosocial measures
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average branched-chain amino acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in branched-chain amino acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of Severe Rotavirus Gastroenteritis
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of Locoregional control (LRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to death from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Inter-rater agreement for stroke volume (SV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inter-rater agreement for peak velocity (Vpk)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of successful fluid bolus administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intervention adherence rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain Reduction change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional score change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intraocular pressure change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Correct Responses to Questionnaire Items
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in respiratory work of breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in HDL concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in LDL concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Sustained Virologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Maintained HCV RNA Levels in Liver and Serum Less Than Lower Limit of Quantification (LLOQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet Inhibition Effect of Clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 2 Year Disease Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects With Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above the Cut-off Value for Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-human Papillomavirus 16 and 18 (Anti-HPV-16 and Anti-HPV-18) Antibody Concentrations Above the Cut-off Value for Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HPV-16/18 Antibody Titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anthropometric parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes